Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings while delivering major clinical milestones. Net loss of $61.8M was narrower than the $68.0M expected, resulting in a GAAP EPS of -$0.84 vs. -$0.93 consensus. The Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis met all clinical endpoints, and a robust cash position of $537.0M extends the runway to mid-2028. Management confirmed the HS BLA submission remains on track for late September 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: MoonLake Immunotherapeutics(MLTX) the EBIT is -61.66 M (-1.58%), Beat estimate;the EPS is -0.84 (+3.45%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.06B1.58%
-0.07B11.50%
+0.01B9.92%
EPSExceed expectations
-0.843.45%
-0.9266.44%
+0.08609.89%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf